Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 562Carcinoma, Non-Small-Cell Lung 482Ovarian Neoplasms 326Lung Neoplasms 203Fallopian Tube Neoplasms 152Neoplasms 150Triple Negative Breast Neoplasms 125Esophageal Neoplasms 125Stomach Neoplasms 121Neoplasm Metastasis 119Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 95Squamous Cell Carcinoma of Head and Neck 94Uterine Cervical Neoplasms 79Head and Neck Neoplasms 77Esophageal Squamous Cell Carcinoma 77Recurrence 48Adenocarcinoma of Lung 47Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 31Pancreatic Neoplasms 29Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Colorectal Neoplasms 25

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bladder Urothelial Carcinoma × Paclitaxel × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡